NEW YORK, April 24, 2013 /PRNewswire/ -- Pomerantz
Grossman Hufford Dahlstrom & Gross LLP is investigating claims
on behalf of investors of PROLOR Biotech, Inc. ("PROLOR" or the
"Company") (NYSE: PBTH) (ISIN: US74344F1066) (CUSIP: 74344F106)
concerning the proposed acquisition of PROLOR Biotech, Inc. by OPKO
Health, Inc. in a transaction valued at approximately $480 million.
The investigation concerns whether the PROLOR directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms of
the agreement, PROLOR shareholders will be entitled to receive
0.9951 shares of OPKO Health, Inc. common stock, or a price of
$7.00 per share for each share of
PROLOR common stock. However, at least one analyst has set a
target price of $8.00 per share.
PROLOR shareholders seeking more information about this
acquisition are advised to contact Robert
Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or
888-476-6529, ext. 237.
The firm is also investigating actions on behalf of shareholders
for the following companies: Arbitron Inc., Net1 Ueps Technologies,
Inc., Universal Technical Institute,
Inc., Telanetix, Inc., Somerset Hills Bancorp, BioClinica Inc., and
Gardner Denver, Inc.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and San
Diego, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of defrauded
investors. See www.pomerantzlaw.com.
SOURCE Pomerantz Grossman Hufford
Dahlstrom & Gross LLP